Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company focusing on hematologic malignancies, has announced its upcoming second quarter 2024 financial results report. The company will host a live conference call and webcast on Wednesday, July 31, 2024, at 8:30 a.m. ET to present the results and provide a business update. Interested parties can access the call via phone or webcast, with details available on the company's website. An archived replay of the webcast will be accessible for approximately 30 days after the call.
Syros Pharmaceuticals (NASDAQ:SYRS), una compagnia biotecnologica focalizzata sulle malignità ematologiche, ha annunciato il suo prossimo rapporto finanziario del secondo trimestre 2024. L'azienda ospiterà una conference call e webcast dal vivo mercoledì 31 luglio 2024, alle 8:30 a.m. ET, per presentare i risultati e fornire un aggiornamento aziendale. Le parti interessate possono accedere alla chiamata telefonicamente o tramite webcast, con dettagli disponibili sul sito web dell'azienda. Una registrazione archiviata del webcast sarà accessibile per circa 30 giorni dopo la chiamata.
Syros Pharmaceuticals (NASDAQ:SYRS), una compañía biofarmacéutica centrada en neoplasias hematológicas, ha anunciado su próximo informe financiero del segundo trimestre de 2024. La empresa llevará a cabo una llamada de conferencia y transmisión en vivo el miércoles 31 de julio de 2024, a las 8:30 a.m. ET para presentar los resultados y proporcionar una actualización comercial. Las partes interesadas pueden acceder a la llamada por teléfono o webcast, con detalles disponibles en el sitio web de la empresa. Una repetición archivada de la transmisión estará accesible durante aproximadamente 30 días después de la llamada.
Syros Pharmaceuticals (NASDAQ:SYRS)는 혈액암에 초점을 맞춘 바이오 제약 회사로, 2024년 2분기 재무 결과 보고서를 발표할 예정이라고 발표했습니다. 이 회사는 2024년 7월 31일 수요일, 오전 8:30 (ET)에 결과를 발표하고 비즈니스 업데이트를 제공하기 위해 실시간 컨퍼런스 콜 및 웹캐스트를 진행합니다. 관심 있는 분들은 전화나 웹캐스트를 통해 콜에 참여할 수 있으며, 자세한 사항은 회사 웹사이트에서 확인할 수 있습니다. 웹캐스트의 녹화 재생본은 콜 후 약 30일 동안 접근할 수 있습니다.
Syros Pharmaceuticals (NASDAQ:SYRS), une entreprise biopharmaceutique axée sur les malignités hématologiques, a annoncé son prochain rapport financier du deuxième trimestre 2024. L'entreprise organisera une conférence téléphonique en direct et un webinaire le mercredi 31 juillet 2024, à 8h30 (ET) pour présenter les résultats et fournir une mise à jour de l'entreprise. Les parties intéressées peuvent accéder à l'appel par téléphone ou par webinaire, les détails étant disponibles sur le site Web de l'entreprise. Un enregistrement archivé du webinaire sera accessible pendant environ 30 jours après l'appel.
Syros Pharmaceuticals (NASDAQ:SYRS), ein biopharmazeutisches Unternehmen, das sich auf hämatologische Malignome konzentriert, hat seinen bevorstehenden Finanzbericht für das zweite Quartal 2024 angekündigt. Das Unternehmen wird am Mittwoch, den 31. Juli 2024, um 8:30 Uhr ET eine Live-Konferenzschaltung und Webcast veranstalten, um die Ergebnisse zu präsentieren und ein Unternehmensupdate bereitzustellen. Interessierte Parteien können die Sitzung per Telefon oder Webcast verfolgen, wobei die Einzelheiten auf der Website des Unternehmens verfügbar sind. Eine archivierte Wiederholung des Webcasts wird für etwa 30 Tage nach dem Anruf zugänglich sein.
- None.
- None.
To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 64947. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the call.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724051062/en/
Syros
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com
Investor
Amanda Isacoff
Precision AQ
212-362-1200
amanda.isacoff@precisionaq.com
Source: Syros Pharmaceuticals
FAQ
When will Syros Pharmaceuticals (SYRS) report its Q2 2024 financial results?
How can investors access Syros Pharmaceuticals' (SYRS) Q2 2024 earnings call?
What time is Syros Pharmaceuticals' (SYRS) Q2 2024 earnings call scheduled for?
How long will the replay of Syros Pharmaceuticals' (SYRS) Q2 2024 earnings call be available?
